Halozyme Therapeutics Inc (HALO)

Net profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	281,594	253,908	233,705	181,636	202,129	211,197	366,150	434,923	402,710	409,104	228,724	163,083	129,085	21,524	-39,698	-80,139	-72,240	-39,969	-42,804	-51,073
Revenue (ttm)	US$ in thousands	810,397	762,509	752,443	685,200	643,040	566,152	478,768	464,176	435,810	457,564	408,802	329,314	267,594	199,556	180,470	164,397	195,992	202,559	181,885	177,939
Net profit margin		34.75%	33.30%	31.06%	26.51%	31.43%	37.30%	76.48%	93.70%	92.40%	89.41%	55.95%	49.52%	48.24%	10.79%	-22.00%	-48.75%	-36.86%	-19.73%	-23.53%	-28.70%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $281,594K ÷ $810,397K
= 34.75%

Halozyme Therapeutics Inc.'s net profit margin, which represents the percentage of revenue that translates to profit after all expenses are deducted, has exhibited some fluctuations over the past quarters. The net profit margin was relatively high in Q2 2022 and Q1 2022, standing at 75.11% and 92.23% respectively, indicating efficient cost management and strong revenue generation relative to expenses during those periods.

However, there has been a noticeable decline in the net profit margin in subsequent quarters. The net profit margin decreased to 30.62% in Q4 2022 and continued to vary between 25.76% and 33.96% in 2023. This suggests that the company may be facing challenges in controlling costs or experiencing fluctuations in its revenue streams in the more recent periods.

It is important for investors and stakeholders to further investigate the reasons behind these fluctuations in the net profit margin to assess the overall financial health and operational efficiency of Halozyme Therapeutics Inc.